



## ASO Author Reflections: Surgical Treatment for Male Breast Cancer in the Modern Era

Candice A. M. Sauder, MD<sup>1,2</sup>

<sup>1</sup>Department of Surgery, University of California, Davis Medical Center, Sacramento, CA; <sup>2</sup>Division of Surgical Oncology, UC Davis Comprehensive Cancer Center, Sacramento, CA

### PAST

Male breast cancer has often been an afterthought in the world of breast cancer research, which is not surprising as it constitutes < 1% of all new breast cancers.<sup>1</sup> Almost all of the original work looking at de-escalating local therapy, including the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-06 study, excluded male participants, and, currently, the gold-standard surgical treatment recommendation for men is mastectomy.<sup>2,3</sup> In the current era, many men are considering breast-conserving therapy (BCT) for treatment; however, no one has directly compared this with mastectomy.

### PRESENT

Due to the limited number of male breast cancer cases, this question has been unable to be prospectively examined to date. Therefore, we used the National Cancer Database (NCDB) to look retrospectively at a similar population to the female population used in the NSABP B-06 study (stage I or II breast cancer patients who underwent partial mastectomy, BCT, or mastectomy), as well as mastectomy with radiation, which was not included in their study. Our data showed that while most men underwent mastectomy, the gold standard, a substantial population underwent some

form of breast conservation (12.4% BCT, 8.2% partial mastectomy alone). Using our model, after controlling for group differences, we found that BCT translated into an improved overall survival over partial mastectomy alone or mastectomy, for all groups.<sup>4</sup> We suggest BCT is a viable option and is possibly preferred to mastectomy in male breast cancer patients.

### FUTURE

In this study, retrospective data from a large national cohort were examined to determine the viability of BCT for male breast cancer patients. Unlike prior studies in women, the study showed an improved survival for BCT. This difference from prior female data may be due to selection bias or, more likely, that male breast cancer is a unique entity. A prospective study is needed to validate the improved survival seen in this cohort of male breast cancer patients. Additionally, other studies have shown decreased male compliance with radiation therapy. Thus, further examination of the utilization of radiation therapy needs to be explored as this is a vital piece of BCT for men, and partial mastectomies alone do not improve survival.<sup>5</sup>

**DISCLOSURE** Candice A.M. Sauder has no conflicts of interest to disclose.

---

ASO Author Reflections is a brief invited commentary on the article “Is Breast-Conserving Therapy Appropriate for Male Breast Cancer Patients? A National Cancer Database Analysis”, Ann Surg Oncol. Epub 13 Feb 2019 (<https://doi.org/10.1245/s10434-019-07159-4>).

---

© Society of Surgical Oncology 2019

First Received: 3 April 2019;  
Published Online: 9 May 2019

C. A. M. Sauder, MD  
e-mail: [camsauder@ucdavis.edu](mailto:camsauder@ucdavis.edu)

### REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin*. 2018;68:7–30.
2. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. *N Engl J Med*. 1985;312:665–673.
3. Cutuli B. Strategies in treating male breast cancer. *Expert Opin Pharmacother*. 2007;8:193–202.

4. Bateni SB, Davidson AJ, Arora M, et al. Is breast-conserving therapy appropriate for male breast cancer patients? A National Cancer Database Analysis. *Ann Surg Oncol*. 2019. <https://doi.org/10.1245/s10434-019-07159-4>.
5. Cloyd JM, Hernandez-Boussard T, Wapnir IL. Poor compliance with breast cancer treatment guidelines in men undergoing breast-conserving surgery. *Breast Cancer Res Treat*. 2013;139:177–182.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.